The discovery of the mechanism(s) by which arterial occlusive events arose in CML patients would help in the management of patients treated with BCR-ABL TKIs and implement risk minimization measures. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.